Johnson Paula A 4

What Happened
Paula A. Johnson, a director of Johnson & Johnson (JNJ), received a grant of 975 deferred share units (DSUs) on April 23, 2026. The filing reports the grant as a derivative award with an acquisition price of $0.00 (reported value $0) because the DSUs represent a future cash settlement rather than immediate stock. This is a compensation grant to a director, not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-04-23 (filed with the SEC on 2026-04-27).
• Transaction code: A (award/grant of a derivative).
• Units granted: 975 DSUs; reported price per unit: $0.00; reported cash value: $0 (DSUs valued at settlement).
• Shares owned after transaction: not specified in the provided excerpt.
• Footnotes:
  • F1: These are DSUs under the Issuer’s Amended and Restated Deferred Fee Plan for Directors; they are cash‑settled when the director leaves the board, each DSU equaling the fair market value of one share at settlement.
  • F2: Dividend equivalent rights accrue on the DSUs in connection with the company’s quarterly dividend.
• Timeliness: Filing appears timely (transaction 4/23/2026, Form 4 filed 4/27/2026).

Context
DSUs are deferred, cash‑settled compensation for directors and do not represent immediate ownership of shares or an immediate purchase/sale signal. Such grants are routine for non‑employee directors and reflect compensation arrangements rather than an insider making a market bet.